FTC Says Pay-for-Delay Settlements Rise to Most Since ’03

Patent dispute settlements including so-called pay-for-delay deals between branded and generic drug companies jumped to 40 in the year ended in September 2012 from 28 the previous year, The U.S. Federal Trade Commission said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.